Trial record 19 of 1323 for:    Open Studies | "Stem Cells"

Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies

This study is currently recruiting participants.
Verified January 2014 by M.D. Anderson Cancer Center
Information provided by (Responsible Party):
M.D. Anderson Cancer Center Identifier:
First received: March 5, 2009
Last updated: January 6, 2014
Last verified: January 2014

The goal of this clinical research study is to learn if thiotepa, busulfan, and clofarabine, when given before an allogeneic (bone marrow , blood, or cord blood cells) or haploidentical (bone marrow) stem cell transplantation can help to control cancers of the bone marrow and lymph node system. The safety of this treatment will also be studied.

Condition Intervention Phase
Stem Cell Transplantation
Drug: Thiotepa
Drug: Clofarabine
Drug: Busulfan
Procedure: Allogeneic Stem Cell Transplantation
Drug: Thymoglobulin (ATG)
Drug: G-CSF (Filgrastim)
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies

Resource links provided by NLM:

Further study details as provided by M.D. Anderson Cancer Center:

Primary Outcome Measures:
  • Relapse-free Survival Rate [ Time Frame: 100 days post-transplant ] [ Designated as safety issue: No ]
    Number of participants out of total participants without detection of histologic diagnosis of recurrent disease on day 100 following stem cell transplant.

Estimated Enrollment: 60
Study Start Date: March 2009
Estimated Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Thio-Clo-Bu with Allo SCT

Pre-transplant conditioning regimen:

Thiotepa (Thio) + Clofarabine (Clo) + Busulfan (Blu) + Allogeneic Stem Cell Transplantation (Allo SCT) + ATG + G-CSF

Drug: Thiotepa
5 mg/kg through a central venous catheter (CVC) over 2 hours on Day -8.
Other Name: Thio
Drug: Clofarabine
40 mg/m^2 through a central venous catheter (CVC) over 1 hour daily on 4 consecutive days (Days -6 through -3).
Other Names:
  • Clo
  • Clofarex
  • Clolar
Drug: Busulfan

Test dose of 0.5 mg/kg through a central venous catheter (CVC)over 30 minutes on Day -7.

High dose through a central venous catheter (CVC) over 3 hours on Days -5, -4, and -3.

Other Names:
  • Busulfex
  • Myleran
Procedure: Allogeneic Stem Cell Transplantation
Infusion of stem cells through through a central venous catheter (CVC) On Day 0.
Other Names:
  • ASCT
  • SCT
Drug: Thymoglobulin (ATG)
1.25 mg/kg by vein on Day -4 and 1.75 mg/kg on Day -3.
Other Name: Antithymocyte globulin
Drug: G-CSF (Filgrastim)
5 µg/kg Injection under the skin once a day, starting 1 week after transplant, until blood cell levels return to normal.
Other Name: Neupogen

  Show Detailed Description


Ages Eligible for Study:   up to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Diagnosed with one of the following diseases:
  2. Acute myelogenous leukemia (AML) in induction failure, relapse, past first remission, or CR1 considered at risk for relapse
  3. Myelodysplastic syndromes with International Prognostic Scoring System score (IPSS score) >/= 2 or myelodysplasia that has not responded to chemotherapy
  4. Biphenotypic leukemia
  5. Acute lymphocytic leukemia with induction failure, first complete remission with high risk cytogenetics (e.g. Philadelphia positive chromosome, t(4:11) Remission requiring more than 2 chemotherapy to achieve remission, or any stage beyond CR1
  6. Chronic Myelogenous Leukemia (CML): second chronic phase, accelerated phase or blast crises with less than 10% blasts in the bone marrow, or CR1 and resistance to Gleevec or other tyrosine kinase inhibitors
  7. Non-Hodgkin's Lymphoma - induction failures, second or third complete remission, or relapse (including relapse post autologous hematopoietic stem cell transplant)
  8. Hodgkin's disease - induction failure, second or later complete remission, or relapse (including relapse post autologous hematopoietic stem cell transplant).
  9. Chronic Lymphocytic Leukemia that has failed induction therapy or Rai Stages 2-4
  10. Related or unrelated donor which is HLA-matched or mismatched in 1 HLA A, B, C, DR, or DQ locus is acceptable (i.e. >/= 9/10 matched related or unrelated donor, matched with molecular high-resolution technique per current std. for BMT program). Cord blood units must match patient at 4, 5, or 6/6 HLA class 1 serological & II molecular antigens with a min. of 2 x 10e7 TNC/kg recipient weight in the pre-thawed fraction. For patient lacking a matched related or unrelated donor or acceptable cord blood unit(s), a related haploidentical donor (</= 7/8 allele matched at A, B, C, DR loci) may be used.
  11. Age </= 60 years.
  12. Lansky performance score >/= 50% for patients </= 16 years of age, or Zubrod performance status score of 0-2 for patients > 16 years of age.
  13. Cardiac function - left ventricular ejection fraction >/= 40%.
  14. Pulmonary function - diffusion capacity of at least 50% predicted. Children unable to perform pulmonary function tests (e.g. less than 7 years old) pulse oximetry of >/= 92% on room air.
  15. Serum creatinine < 1.6 mg/dL or creatinine clearance >/= 50 ml/min.
  16. SGPT </= 200 IU/mL, serum bilirubin < 1.5 x normal.
  17. Written informed consent and assent as is age appropriate.
  18. No active infection.

Exclusion Criteria:

  1. Pregnancy in women of child bearing potential (pregnancy test performed within 2 weeks of study entry).
  2. HIV positive (highly immunosuppressive treatment)
  3. Active CNS leukemia
  4. Chronic or active Hepatitis B or Hepatitis C. If questions about liver health discuss with PI and strongly consider liver biopsy.
  Contacts and Locations
Please refer to this study by its identifier: NCT00857389

Contact: Laura L. Worth, MD, PhD 713-792-6620

United States, Texas
UT MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Principal Investigator: Laura L. Worth, MD, PhD         
Sponsors and Collaborators
M.D. Anderson Cancer Center
Principal Investigator: Laura L. Worth, MD, PhD UT MD Anderson Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: M.D. Anderson Cancer Center Identifier: NCT00857389     History of Changes
Other Study ID Numbers: 2008-0363
Study First Received: March 5, 2009
Last Updated: January 6, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by M.D. Anderson Cancer Center:
Stem Cell
Allogeneic Stem Cell Transplant
Blood And Marrow Transplantation
Bone marrow
Lymph node system
Antithymocyte globulin

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antilymphocyte Serum
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Therapeutic Uses
Myeloablative Agonists
Adjuvants, Immunologic processed this record on April 17, 2014